Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.

Tourmaline Bio Inc

TRML
17,74
0,20 (1,14%)
Pre Mercato
Ultimo aggiornamento: 14:15:07
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
27/1/202513:00GLOBETourmaline Bio to Present at the Guggenheim Securities SMID..
10/1/202513:30GLOBETourmaline Strengthens Cardiovascular Scientific Advisory..
10/12/202422:08EDGAR2Form 8-K - Current report
10/12/202414:44EDGAR2Form 8-K - Current report
10/12/202414:30GLOBETourmaline Bio Highlights Cardiovascular Inflammation Focus..
14/11/202423:05EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
14/11/202415:45EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
14/11/202413:30GLOBETourmaline Bio to Host Investor Day on Tuesday, December 10,..
08/11/202420:17EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
07/11/202423:21EDGAR2Form S-3 - Registration statement under Securities Act of..
07/11/202414:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202413:37EDGAR2Form 8-K - Current report
07/11/202413:30GLOBETourmaline Bio Reports Third Quarter 2024 Financial Results..
31/10/202412:30GLOBETourmaline Bio to Present at Upcoming Investor Conferences
15/10/202413:30GLOBETourmaline Bio to Host Expert Webinar on Human Genetic..
11/10/202413:30GLOBETourmaline Bio to Showcase Two Poster Presentations at the..
10/10/202422:25EDGAR2Form 8-K - Current report
08/10/202413:30GLOBETourmaline Bio Announces Formation of Cardiovascular..
11/9/202422:18EDGAR2Form 8-K - Current report
05/9/202422:19EDGAR2Form 8-K - Current report
03/9/202413:45GLOBETourmaline Bio to Present at Upcoming Investor Conferences
22/8/202422:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202400:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202414:46EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202413:44EDGAR2Form 8-K - Current report
08/8/202413:30GLOBETourmaline Bio Reports Second Quarter 2024 Financial Results..
02/8/202422:30GLOBETourmaline Bio Presents Phase 2 TRANQUILITY Study Design at..
27/6/202414:05GLOBETourmaline Bio Announces the Promotion of Ryan Robinson to..
07/6/202422:04EDGAR2Form 8-K - Current report
07/6/202422:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202422:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202413:10GLOBETourmaline Bio to Present at the Jefferies Global Healthcare..
16/5/202413:00GLOBETourmaline Bio Initiates Clinical Development of TOUR006 for..
13/5/202422:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/5/202413:15EDGAR2Form 8-K - Current report
13/5/202413:00GLOBETourmaline Bio Reports First Quarter 2024 Financial Results..
02/4/202413:00GLOBEAvalo Therapeutics Appoints Biotech Leaders to Board of..
19/3/202412:00GLOBETourmaline Bio Reports Fourth Quarter and Full Year 2023..
27/2/202413:30GLOBETourmaline Bio to Present at Upcoming Investor Conferences
15/2/202403:08EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
15/2/202402:51EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09/2/202422:22EDGAR2Form SC 13G - Statement of acquisition of beneficial..
01/2/202414:00GLOBETourmaline Bio to Present at the Guggenheim Healthcare Talks..
29/1/202422:01GLOBETourmaline Bio Announces Closing of $172.5 Million Public..
Apertura: Min: Max:
Chiusura: 17,54

La tua Cronologia

Delayed Upgrade Clock

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network